Evaluation the effect of empagliflozin on diastolic function prediabetic people

Evaluation of empagliflozin on diastolic function in prediabetic people with body mass index>30 kg/m2 Imam Hossein Hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220910055934N1

Enrollment

Registered

2022-11-01

Start date

2022-10-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diastolic dysfunction. Condition 2: Obesity. Condition 3: pre-diabetic. Left ventricular failure Overweight and obesity

Interventions

Intervention 1: The intervention group will be treated with Empagliflozin 10 mg of Actover pharmaceutical company daily for 3 months. Cardiac function will be measured by Philips echocardiography devi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: age more than 18 years old prediabetic (100<FBS<125) BMI more than 30 kg/m2 stability in cardiac symptom in the last 3 months

Exclusion criteria

Exclusion criteria: Using empagliflozin during the last 3 months

Design outcomes

Primary

Measure	Time frame
The effect of empagliflozin in improving the E/e ratio after 3 months treatment. Timepoint: E/e dosing before the start of the study and after 3 months of continuous drug use. Method of measurement: Echocardiography.;FBS. Timepoint: Before the intervention and 3 months after taking Empagliflozin. Method of measurement: Blood test.;The effect of Empagliflozin on blood pressure. Timepoint: Blood pressure measurement before the start of the study and after 3 months of continuous use. Method of measurement: Pressure gauge device.;The effect of empagliflozin on lowering blood sugar by measuring 2hpp. Timepoint: Blood sugar measurement using 2hpp before the intervention and 3 months after taking Empagliflozin. Method of measurement: blood test.;The effect of empagliflozin on lowering blood sugar by measuring HbA1c. Timepoint: Blood sugar measurement using HbA1C before the intervention and 3 months after taking Empagliflozin. Method of measurement: blood test.	—

Measure

Time frame

The effect of empagliflozin in improving the E/e ratio after 3 months treatment. Timepoint: E/e dosing before the start of the study and after 3 months of continuous drug use. Method of measurement: Echocardiography.;FBS. Timepoint: Before the intervention and 3 months after taking Empagliflozin. Method of measurement: Blood test.;The effect of Empagliflozin on blood pressure. Timepoint: Blood pressure measurement before the start of the study and after 3 months of continuous use. Method of measurement: Pressure gauge device.;The effect of empagliflozin on lowering blood sugar by measuring 2hpp. Timepoint: Blood sugar measurement using 2hpp before the intervention and 3 months after taking Empagliflozin. Method of measurement: blood test.;The effect of empagliflozin on lowering blood sugar by measuring HbA1c. Timepoint: Blood sugar measurement using HbA1C before the intervention and 3 months after taking Empagliflozin. Method of measurement: blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoxana Sadeghi

Shahid Beheshti University of Medical Sciences

roxan.sadeghi@sbmu.ac.ir+98 21 7343 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026